Statin use and non-melanoma skin cancer risk

A meta-analysis of randomized controlled trials and observational studies

Keming Yang, Andrew Marley, Huilin Tang, Yiqing Song, Jean Y. Tang, Jiali Han

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Existing evidence of the association between statin use and nonmelanoma skin cancer (NMSC) risk has been inconsistent. Objective: To maximize statistical power to synthesize prospective evidence on this relationship. Materials and Methods: PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrial.gov were systematically searched up to December 11, 2016. A random-effects meta-analysis was conducted to calculate summary estimates. Results: Our meta-analysis of 14 randomized controlled trials (RCTs) including 63,157 subjects showed no significant association between statin use and NMSC risk (RR = 1.09, 95%CI = 0.85-1.39). However, meta-analysis of four observational studies including 1,528,215 participants showed significantly increased risk of NMSC among statin users compared to non-users (RR = 1.11, 95%CI = 1.02-1.22). Furthermore, ever using lipophilic statins (RR = 1.14, 95%CI = 1.04-1.24) or lowerpotency statins (RR = 1.14, 95%CI = 1.03-1.26), as well as usage of any statin longer than one year (RR = 1.14, 95%CI = 1.09-1.18) were significantly associated with increased NMSC risk based on observational studies. Conclusions: Evidence from observational studies supported an association between statin use and increased NMSC risk. This finding should be interpreted with caution due to modest number of included studies, possible between-study heterogeneity and inherent limitations of observational studies.

Original languageEnglish (US)
Pages (from-to)75411-75417
Number of pages7
JournalOncotarget
Volume8
Issue number43
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Skin Neoplasms
Observational Studies
Meta-Analysis
Randomized Controlled Trials
PubMed

Keywords

  • Meta-analysis
  • Non-melanoma skin cancer
  • Statins

ASJC Scopus subject areas

  • Oncology

Cite this

Statin use and non-melanoma skin cancer risk : A meta-analysis of randomized controlled trials and observational studies. / Yang, Keming; Marley, Andrew; Tang, Huilin; Song, Yiqing; Tang, Jean Y.; Han, Jiali.

In: Oncotarget, Vol. 8, No. 43, 01.01.2017, p. 75411-75417.

Research output: Contribution to journalArticle

Yang, Keming ; Marley, Andrew ; Tang, Huilin ; Song, Yiqing ; Tang, Jean Y. ; Han, Jiali. / Statin use and non-melanoma skin cancer risk : A meta-analysis of randomized controlled trials and observational studies. In: Oncotarget. 2017 ; Vol. 8, No. 43. pp. 75411-75417.
@article{128685005e3146568281d07b2548df4e,
title = "Statin use and non-melanoma skin cancer risk: A meta-analysis of randomized controlled trials and observational studies",
abstract = "Background: Existing evidence of the association between statin use and nonmelanoma skin cancer (NMSC) risk has been inconsistent. Objective: To maximize statistical power to synthesize prospective evidence on this relationship. Materials and Methods: PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrial.gov were systematically searched up to December 11, 2016. A random-effects meta-analysis was conducted to calculate summary estimates. Results: Our meta-analysis of 14 randomized controlled trials (RCTs) including 63,157 subjects showed no significant association between statin use and NMSC risk (RR = 1.09, 95{\%}CI = 0.85-1.39). However, meta-analysis of four observational studies including 1,528,215 participants showed significantly increased risk of NMSC among statin users compared to non-users (RR = 1.11, 95{\%}CI = 1.02-1.22). Furthermore, ever using lipophilic statins (RR = 1.14, 95{\%}CI = 1.04-1.24) or lowerpotency statins (RR = 1.14, 95{\%}CI = 1.03-1.26), as well as usage of any statin longer than one year (RR = 1.14, 95{\%}CI = 1.09-1.18) were significantly associated with increased NMSC risk based on observational studies. Conclusions: Evidence from observational studies supported an association between statin use and increased NMSC risk. This finding should be interpreted with caution due to modest number of included studies, possible between-study heterogeneity and inherent limitations of observational studies.",
keywords = "Meta-analysis, Non-melanoma skin cancer, Statins",
author = "Keming Yang and Andrew Marley and Huilin Tang and Yiqing Song and Tang, {Jean Y.} and Jiali Han",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20034",
language = "English (US)",
volume = "8",
pages = "75411--75417",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "43",

}

TY - JOUR

T1 - Statin use and non-melanoma skin cancer risk

T2 - A meta-analysis of randomized controlled trials and observational studies

AU - Yang, Keming

AU - Marley, Andrew

AU - Tang, Huilin

AU - Song, Yiqing

AU - Tang, Jean Y.

AU - Han, Jiali

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Existing evidence of the association between statin use and nonmelanoma skin cancer (NMSC) risk has been inconsistent. Objective: To maximize statistical power to synthesize prospective evidence on this relationship. Materials and Methods: PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrial.gov were systematically searched up to December 11, 2016. A random-effects meta-analysis was conducted to calculate summary estimates. Results: Our meta-analysis of 14 randomized controlled trials (RCTs) including 63,157 subjects showed no significant association between statin use and NMSC risk (RR = 1.09, 95%CI = 0.85-1.39). However, meta-analysis of four observational studies including 1,528,215 participants showed significantly increased risk of NMSC among statin users compared to non-users (RR = 1.11, 95%CI = 1.02-1.22). Furthermore, ever using lipophilic statins (RR = 1.14, 95%CI = 1.04-1.24) or lowerpotency statins (RR = 1.14, 95%CI = 1.03-1.26), as well as usage of any statin longer than one year (RR = 1.14, 95%CI = 1.09-1.18) were significantly associated with increased NMSC risk based on observational studies. Conclusions: Evidence from observational studies supported an association between statin use and increased NMSC risk. This finding should be interpreted with caution due to modest number of included studies, possible between-study heterogeneity and inherent limitations of observational studies.

AB - Background: Existing evidence of the association between statin use and nonmelanoma skin cancer (NMSC) risk has been inconsistent. Objective: To maximize statistical power to synthesize prospective evidence on this relationship. Materials and Methods: PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrial.gov were systematically searched up to December 11, 2016. A random-effects meta-analysis was conducted to calculate summary estimates. Results: Our meta-analysis of 14 randomized controlled trials (RCTs) including 63,157 subjects showed no significant association between statin use and NMSC risk (RR = 1.09, 95%CI = 0.85-1.39). However, meta-analysis of four observational studies including 1,528,215 participants showed significantly increased risk of NMSC among statin users compared to non-users (RR = 1.11, 95%CI = 1.02-1.22). Furthermore, ever using lipophilic statins (RR = 1.14, 95%CI = 1.04-1.24) or lowerpotency statins (RR = 1.14, 95%CI = 1.03-1.26), as well as usage of any statin longer than one year (RR = 1.14, 95%CI = 1.09-1.18) were significantly associated with increased NMSC risk based on observational studies. Conclusions: Evidence from observational studies supported an association between statin use and increased NMSC risk. This finding should be interpreted with caution due to modest number of included studies, possible between-study heterogeneity and inherent limitations of observational studies.

KW - Meta-analysis

KW - Non-melanoma skin cancer

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85030115496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030115496&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20034

DO - 10.18632/oncotarget.20034

M3 - Article

VL - 8

SP - 75411

EP - 75417

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -